respiratori
diseas
like
lung
cancer
inflammatori
diseas
chronic
obstruct
pulmonari
diseas
copd
asthma
respiratori
infect
pulmonari
fibrosi
major
caus
death
global
current
avail
treatment
option
diseas
limit
efficaci
approv
inhal
corticosteroid
earli
open
major
breakthrough
path
treatment
airway
diseas
even
year
still
mainstay
respiratori
diseas
therapi
howev
sever
limit
come
manag
chronic
diseas
condit
along
line
research
doublestrand
rna
dsrna
discov
regul
gene
function
rna
interfer
rnai
silenc
mechan
mechan
repres
new
power
therapeut
approach
treatment
prevent
respiratori
diseas
alter
gene
express
differ
rna
molecul
mediat
rnai
short
interf
rna
sirna
long
dsrna
microrna
mirna
short
hairpin
rna
shrna
among
molecul
approach
oligonucleotid
therapi
emerg
newer
effect
class
oligonucleotid
defin
polynucl
acid
chain
may
modifi
unmodifi
consist
variou
function
group
base
use
sourc
nucleotid
contain
five
base
pair
two
purin
deriv
adenin
guanin
rest
pyrimidin
deriv
cytosin
thymin
uracil
class
substanc
function
base
sever
approach
name
rnai
mirna
sirna
antisens
aptam
immunomodulatori
decoy
approach
approach
earli
phase
develop
howev
sever
limit
current
state
small
molecul
therapi
thu
use
oligonucleotid
emerg
advanc
treatment
respiratori
diseas
cover
wide
rang
target
applic
oligonucleotid
list
pcr
polymeras
chain
reaction
primer
rna
sirna
antisens
studi
melt
point
optim
oligonucleotid
molecular
diagnost
gene
therapi
microarray
fluoresc
situ
hybrid
fish
fluoresc
reson
energi
transfer
fret
short
singl
strand
oligodeoxynucleotid
capabl
modifi
rna
alter
protein
express
base
upon
mechan
action
categor
two
class
rnase
hdepend
oligonucleotid
stimul
mrna
degrad
antisens
drug
act
rnase
hdepend
mechan
enzym
rnase
h
caus
hydrolysi
rna
strand
rnadna
duplex
shown
fig
effici
downregul
protein
mrna
express
target
site
mrna
b
stericblock
oligonucleotid
hamper
process
splice
translat
oligonucleotid
effect
target
specif
codon
ie
aug
initi
codon
capabl
target
caus
develop
diseas
aso
potenti
use
success
therapi
compar
convent
therapi
noncod
rna
distinct
role
gene
regul
also
specif
act
one
mrna
target
sirna
respons
gene
silenc
post
transcript
level
caus
rna
interfer
rnai
rnai
natur
process
caus
gene
silenc
mrna
degrad
convent
sirna
contain
nucleotid
along
two
nucleotid
overhang
end
mostli
tt
uu
potenc
enhanc
elong
length
doubl
strand
rna
dsrna
although
potenti
therapeut
util
yet
certain
challeng
util
clinic
practic
reduc
stabil
poor
deliveri
mirna
singl
strand
rna
consist
nucleotid
produc
primari
mirna
via
action
two
rnaseiii
type
proteinsdrosha
nucleu
dicer
cytoplasm
hinder
translat
process
accumul
mrna
process
bodi
pbodi
play
vital
role
variou
process
cell
divis
cell
death
breakdown
fat
neuron
patter
hematopoiet
differenti
immun
mirna
act
multipl
target
caus
mrna
degrad
also
face
limit
term
instabl
poor
deliveri
addit
also
potenti
use
variou
complex
disord
differ
type
cancer
neurodegen
disord
comparison
mirna
sirna
shown
tabl
singl
strand
dna
rna
molecul
bind
strongli
definit
target
less
immunogen
physic
stabl
subject
larg
scale
product
rel
reason
cost
molecul
mostli
use
therapeut
diagnost
agent
biosen
rna
dna
aptam
differ
sequenc
fold
pattern
even
though
act
similar
target
short
singl
strand
oligodeoxynucleotid
includ
unmethyl
cpg
dinucleotid
particular
region
divid
four
class
depend
upon
structur
variat
type
immun
reaction
stimul
ktypebtyp
cpg
dinucleotid
phosphorothio
backbon
increas
resist
nucleas
digest
lead
enhanc
halflif
stimul
bcell
produc
igm
b
dtypeatyp
molecul
consist
phosphodiest
centr
surround
phosphorothio
termin
nucleotid
caus
matur
plasmacytoid
dendrit
cell
pdc
stimul
product
interferon
c
ctype
substanc
enhanc
product
bcell
pdc
ptype
substanc
consist
doubl
palindrom
make
hairpin
like
structur
gc
rich
stimul
secret
type
iifn
brief
classif
oligonucleotid
shown
tabl
oligonucleotid
util
last
two
decad
therapeut
properti
majorli
use
either
inhibit
gene
protein
express
follow
area
use
neurodegen
disord
oligonucleotid
use
effect
therapi
treatment
huntington
diseas
hd
autosom
diseas
caus
mutat
singl
allel
oligonucleotid
target
alter
messeng
rna
mrna
decreas
synthesi
caus
proteinhuntingtin
aso
also
use
therapi
treatment
spinal
muscular
atrophi
sma
amyotroph
later
sclerosi
al
spinocerebellar
ataxia
respiratori
disord
oligonucleotid
administ
inhal
treatment
asthma
copd
fewer
side
effect
molecul
directli
target
lung
addit
uptak
usual
enhanc
target
site
lead
prolong
durat
action
cancer
antisens
oligonucleotid
emerg
new
therapeut
approach
treatment
variou
type
cancer
wherebi
attach
mrna
inhibit
gene
translat
howev
nonspecif
protein
bind
effici
deliveri
appear
major
hurdl
use
cancer
treatment
diabet
retinopathi
antisens
oligonucleotid
eg
current
trial
treatment
diabet
retinopathi
act
regul
signal
pathway
multipl
growth
factor
involv
ocular
angiogenesi
vascular
leakag
provid
sever
advantag
name
increas
halflif
lesser
degrad
improv
safeti
profil
interest
note
oligonucleotid
current
approv
vitraven
novarti
new
york
ny
usa
use
cytomegaloviru
retin
drug
directli
administ
site
diseas
intravitr
dna
antisens
oligonucleotid
aso
molecul
act
modul
express
target
gene
bind
mrna
therebi
prevent
translat
concept
first
propos
zamecnik
stephenson
first
evid
report
literatur
suggest
oligonucleotid
might
use
therapeut
intervent
sinc
aon
technolog
develop
wide
array
therapeut
purpos
grow
interest
approach
risen
fact
sever
copi
protein
produc
mrna
molecul
danjou
team
patent
formul
antisens
oligonucleotid
target
gene
code
phosphodiesteras
use
either
analyt
agent
therapi
case
asthma
copd
bronchiti
pulmonari
fibrosi
lead
rise
cyclic
amp
reduct
pde
level
anoth
patent
involv
oligonucleotid
nucleotid
sequenc
correspond
respiratori
syncyti
viru
nucleotid
sequenc
number
respiratori
syncyti
viru
antigenom
invent
also
provid
composit
includ
oligonucleotid
physiolog
accept
carrier
therefor
potenti
effici
approach
target
mrna
rather
protein
furthermor
cpg
oligonucleotid
attach
tolllik
receptor
caus
immun
respons
stimul
intracellular
signal
caus
stimul
proinflammatori
mediat
aptam
bound
tightli
protein
target
hinder
respons
sirna
act
argonaut
rnainduc
silenc
complex
complex
exonucleas
endonucleas
activ
caus
degrad
cellular
mrna
thu
inhibit
translat
also
act
syk
kinas
signal
molecul
respons
inflamm
kinman
yamada
patent
method
administ
oligodeoxynucleotid
treatment
inflammatori
lung
diseas
abl
suppress
immun
respons
cpg
oligodeoxynucleotid
manag
inflammatori
lung
disord
anoth
invent
involv
method
activ
immun
respons
use
combin
immunostimulatori
cpg
oligonucleotid
immunopotenti
cytokin
administ
nucleic
acid
deliveri
complex
caus
antigen
specif
immun
respons
human
anim
order
attain
full
potenti
oligonucleotid
treatment
option
better
methodolog
must
develop
deliv
agent
tissu
cell
target
specif
manner
current
mani
research
work
issu
chemic
modifi
oligonucleotid
use
variou
nanocarri
commonli
use
drug
deliveri
system
respiratori
diseas
polymerbas
lipidbas
peptidebas
among
three
lipidbas
carrier
commonli
use
vector
deliv
rnai
includ
solid
lipid
nanoparticl
cation
liposom
lipidoid
solid
nanostructur
lipid
carrier
phrespons
lipid
liposom
colloid
drug
deliveri
system
consist
lipid
layer
encircl
aqueou
centr
drug
distribut
per
solubl
lipid
layer
hydrophil
core
carrier
enhanc
pharmacokinet
drug
addit
channel
protein
might
develop
liposom
well
allow
passageway
tinys
particl
instanc
ion
antibiot
nutrient
lead
reduc
degrad
proteolyt
enzym
owe
concentr
gradient
differ
drug
might
diffus
via
channel
well
mccaskil
cowork
studi
system
deliveri
cation
liposom
formul
hydrat
freezedri
matrix
hfdm
sirna
lung
epithelium
studi
show
sirna
deliv
murin
lung
cell
administ
intraven
observ
sirna
abl
caus
target
gene
protein
knockdown
part
lung
thu
potenti
use
treatment
lung
epithelium
diseas
anoth
studi
report
formul
cation
liposom
dialkyl
cation
lipid
dotap
studi
abil
deliv
sirna
lung
upon
iv
administr
cation
liposom
made
n
propyl
carbam
hydroiodid
hapcchol
show
increas
buildup
sirna
lung
decreas
express
mrna
ozpolat
cowork
studi
util
neutral
base
nanoliposom
cancer
therapi
found
rel
safer
time
efficaci
cation
liposom
nake
sirna
distribut
sirna
cancer
tissu
anoth
studi
report
formul
steric
stabil
cation
liposom
contain
cpgoligonucleotid
studi
potenti
antiallergen
immunoprotect
liposom
enhanc
durat
immun
defens
cpgoligonucleotid
offer
protect
increas
uptak
bcell
dendrit
cell
macrophag
li
cowork
formul
liposom
antiegfr
aptamerconjugatedchitosan
deliv
erlotinib
oxygen
revers
drug
resist
caus
hypoxia
case
lung
cancer
liposom
shown
improv
stabil
addit
provid
control
discharg
drug
garbuzenko
team
formul
neutral
cation
liposom
carri
doxorubicin
dox
aso
sirna
compar
intratrach
deliveri
liposom
system
administr
elev
peak
concentr
extend
retent
time
liposom
observ
case
intratrach
deliveri
studi
reveal
potenti
liposom
treatment
lung
cancer
mizuta
et
al
studi
potenti
antisens
phosphorothio
oligonucleotid
treatment
influenza
viru
oligonucleotid
found
complementari
translat
codon
pa
gene
paa
influenza
viru
rna
polymeras
therefor
formul
liposom
incorpor
abl
reduc
viral
growth
lung
anoth
studi
otsuka
team
prepar
vitamin
acoupl
liposom
incorpor
sirna
treatment
pulmonari
fibrosi
target
myofibroblast
liposom
inhibit
collagenspecif
chaperon
heat
specif
protein
niosom
defin
vesicl
made
nonion
surfact
use
target
deliveri
drug
wherebi
also
prevent
loss
drug
caus
local
deliveri
drug
molecul
make
bilay
structur
lipophil
region
project
away
aqueou
solvent
hydrophil
region
remain
touch
aqueou
solvent
use
carrier
effect
gene
transport
better
stabil
small
size
studi
report
formul
cation
lipid
teradecyloxi
aqualen
polysorb
niosom
solvent
emulsificationevapor
method
niosom
abl
prevent
dna
degrad
help
entri
cell
anoth
studi
use
cation
niosom
compos
span
dota
pegyl
lipid
intracellular
transport
sirnamirna
niosom
also
incorpor
rna
lead
effici
gene
silenc
human
mesenchym
stem
cell
particl
nm
size
rang
term
nanoparticl
newli
employ
target
drug
deliveri
small
size
rang
allow
nanoparticl
behav
drug
carrier
turn
allow
reach
part
human
bodi
broadli
categor
polymer
inorgan
lipid
base
nanoparticl
polymer
nanoparticl
potenti
applic
diagnosi
diseas
drug
deliveri
due
control
drug
releas
theranost
target
specif
better
therapeut
index
method
drug
deliveri
depend
biocompat
biodegrad
polym
kumar
et
al
demonstr
chitosan
gene
nanoparticl
therapeut
substanc
allerg
asthma
well
prophylaxi
intranas
administr
nanoparticl
taken
macrophag
bronchoepithelium
cell
reduc
airway
hyperrespons
cytokin
level
via
signal
pathway
year
nonmethyl
cpgoligonucleotid
cpgodn
use
potenti
substanc
manag
allerg
asthma
howev
molecul
deliv
high
dose
due
undesir
sideeffect
septic
shock
due
elev
cytokin
level
bodi
overcom
side
effect
nm
poli
lacticcoglycol
acid
encapsul
cpgodn
found
improv
respons
reduc
eosinophil
count
pulmonari
system
allergen
immunocompromis
mice
furthermor
polyethylenimin
base
sirna
deliveri
target
cell
report
xie
et
al
demonstr
murin
model
allerg
asthma
chitosan
nanoparticl
base
imiquimod
cream
natriuret
peptid
receptor
sirna
sinpr
appli
ovasensit
mice
show
decreas
ahr
eosinophil
count
level
proinflammatori
cytokin
includ
cystic
fibrosi
cf
remain
one
lung
diseas
target
gene
therapi
sinc
clinic
trial
viral
nonvir
vector
carri
osman
et
al
demonstr
novel
pegyl
cell
penetr
peptid
cpp
nanoparticl
glycosaminoglycan
gag
effici
deliv
vivo
superior
biodistribut
improv
safeti
profil
effici
gene
transfer
report
luciferas
plasmid
compar
nonpegyl
complex
therefor
peggat
technolog
success
approach
mucoobstruct
lung
diseas
vivo
lewi
lung
carcinoma
studi
aerosol
deliveri
polyethyleneimin
pea
conjug
sirna
studi
report
lung
tumor
progress
inhibit
week
post
aerosol
deliveri
sung
et
al
demonstr
noncoval
bound
pegyl
connect
transform
growth
factor
ctgf
complex
lung
fibrosi
intratrach
administr
copolym
sirna
target
ctgf
signific
decreas
ctgf
express
inflammatori
cytokin
collagen
deposit
observ
mice
model
lung
fibrosi
nafe
et
al
develop
antisens
oligonucleotid
omr
telomeras
inhibitor
load
onto
chitosan
nanoparticl
lung
cancer
observ
omr
reduc
telomeras
activ
lung
cancer
cell
line
nascimento
et
al
report
type
epiderm
growth
factor
receptor
egfr
chitosan
nanoparticl
codeliveri
sirna
cisplatin
codeliveri
higher
therapeut
effect
cross
chemicodrug
resist
barrier
lung
cancer
lead
apoptosi
mitot
failur
phospholipid
base
matrix
use
entrap
hydrophob
hydrophil
drug
improv
pharmacolog
action
drug
better
pharmacokinet
profil
bae
et
al
demonstr
quantum
dot
qd
incorpor
solid
lipid
nanoparticl
sln
synergist
therapeut
activ
sirnapaclitaxel
human
lung
carcinoma
synergist
activ
promot
caspas
mediat
apoptosi
downregul
express
fluoresc
qd
help
observ
situ
nanoparticl
transloc
taratula
et
al
report
multifunct
lipid
nanoparticl
deliv
via
inhal
consist
anticanc
drug
paclitaxel
doxobrubicin
multidrug
resist
associ
peptid
mrp
mrna
target
sirna
along
sirna
mrna
supress
nonpump
cellular
resist
effect
deliveri
drug
sirna
induc
cell
death
lung
tumor
cell
target
gene
silenc
inorgan
nanoparticl
synthes
gold
silver
platinum
cost
effect
polymer
nanoparticl
due
less
viabil
microbi
degrad
tarantula
et
al
report
mesopor
silica
nanoparticl
msn
deliv
drug
molecul
incis
cancer
cell
conjug
deliveri
system
contain
doxorubicin
cisplatin
anticanc
drug
along
sirna
target
mrp
mrna
deliveri
system
report
enhanc
cytotox
effect
anticanc
drug
cond
cowork
studi
gold
nanoparticl
modifi
sirna
target
cmyc
mous
lung
use
rgd
peptid
argglyasp
via
intratrach
instil
peptid
adher
cell
prolifer
bind
integrin
angiogenesi
marker
deliveri
system
suppress
cmyc
inhibit
tumor
prolifer
list
sirnabas
therapeut
clinic
trial
shown
tabl
first
report
antisens
oligonucleotid
recent
report
rna
interfer
rnai
numer
scientif
commun
publish
report
promis
result
oligonucleotid
therapeut
respiratori
disord
oligonucleotid
short
dna
rna
molecul
emerg
therapeut
modal
variou
common
respiratori
diseas
major
obstacl
success
deliveri
rnai
sirna
transloc
across
plasma
membran
subsequ
releas
endosom
compart
biomacromolecul
suscept
degrad
ubiquit
nucleas
hold
neg
surfac
charg
overcom
obstacl
extens
effort
requir
focu
develop
effect
formul
maintain
local
drug
concentr
longer
durat
prevent
fast
clearanc
sirna
comparison
deliveri
system
use
bioadhes
polymer
materi
gain
less
attent
develop
gene
deliveri
formul
natur
synthet
polyc
especi
mucoadhes
chitosan
explor
pulmonari
sirna
deliveri
chitosan
biodegrad
nontox
polymer
materi
investig
transfer
plasmid
dna
pulmonari
epitheli
cell
express
desir
protein
mucoadhes
chitosanbas
nanoparticl
wide
investig
pulmonari
deliveri
sirna
gene
silenc
cholesterollow
properti
also
use
wound
heal
establish
ideal
polymer
materi
deliveri
dna
mucos
tissu
due
good
mucoadhes
characterist
abil
increas
paracellular
transport
modul
tight
junction
intranas
administr
sirna
express
plasmid
shrna
nanochitosan
formul
result
decreas
viral
titer
airway
reactiv
inflamm
respiratori
syncyti
viru
rsv
infect
anim
model
bivasbenita
et
al
deliv
dna
plasmid
encod
eight
hlaa
tcell
epitop
mycobacterium
tuberculosi
formul
chitosan
nanoparticl
transgen
mous
model
via
pulmonari
rout
dna
contain
chitosan
nanoformul
induc
matur
dendrit
cell
pulmonari
administr
dna
plasmid
contain
chitosan
nanoparticl
increas
secret
glud
et
al
investig
pulmonari
gene
silenc
effect
small
interf
lock
nucleic
acid
silna
target
enhancedgreenfluorescentprotein
egfp
lung
bronchoepithelium
upon
intraven
deliveri
nake
silna
intranas
deliveri
nake
silna
chitosan
base
silna
mucoadhes
nanoparticl
signific
reduct
egfp
protein
express
observ
intraven
administr
nake
silna
egfptransgen
mice
intranas
administr
silnachitosan
nanoparticl
also
yield
similar
effect
howev
intranas
administr
nake
silna
caus
knockdown
establish
relationship
structur
properti
chitosanpdna
polyplex
kopinghoggard
et
al
compar
polyplex
ultrapur
chitosan
prefer
molecular
structur
optim
polyethylenimin
polyplex
dnachitosancomplex
deliveri
pulmonari
epithelium
detect
gene
express
report
vector
luciferas
lacz
lung
h
intratrach
administr
mice
model
polyplex
ultrapur
chitosan
found
nontox
higher
dose
patent
grant
rolland
mumper
invent
entitl
chitosan
relat
composit
method
deliveri
nucleic
acid
oligonucleotid
cell
invent
report
nonvir
method
deliveri
nucleic
acid
oligonucleotid
cell
chitosansirna
nanoparticl
deliv
rnai
base
format
interpolyelectrolyt
complex
sirna
duplex
chitosan
report
rapid
uptak
nanoparticl
nih
cell
follow
accumul
h
nanoparticlemedi
knockdown
endogen
enhanc
green
fluoresc
protein
egfp
demonstr
human
lung
carcinoma
cell
murin
periton
macrophag
nasal
administr
formul
show
effect
rna
interfer
bronchiol
epitheli
cell
mice
model
intranas
vaccin
chitosan
base
plasmid
dna
induc
signific
peptid
viru
specif
cytotox
lymphocyt
respons
balbc
mice
substanti
decreas
rsv
titer
antigen
load
record
balbc
mice
vaccin
cocktail
rsv
cdna
chitosan
nanoparticul
mao
et
al
develop
chitosandna
nanoparticl
use
complex
coacerv
process
pulmonari
deliveri
gene
carri
polyepitop
plasmid
encod
eight
known
tcell
epitop
deriv
mycobacterium
tuberculosi
antigen
signific
increas
transfect
effici
observ
conjug
nanoparticl
compar
transferrin
conjug
cell
hela
cell
surfac
function
dendrit
cell
target
chitosan
nanoparticl
examin
nasal
dna
immun
sever
acut
respiratori
syndrom
cov
sarscov
dendrit
cell
ctype
lectin
receptor
ctype
lectin
receptor
found
dendrit
cell
recognit
uptak
pathogen
raghwanshi
et
al
develop
bifunct
fusion
protein
vector
truncat
corestreptavidin
fuse
singl
chain
antibodi
fusion
protein
bound
biotinyl
chitosan
nanoparticl
plasmid
dna
encod
nucleocapsid
protein
load
chitosan
nanoparticl
intranas
dendrit
cell
target
nanoparticl
enhanc
mucos
iga
system
igg
level
nucleocapsid
protein
poli
lactidecoglycolid
plga
anoth
class
biocompat
biodegrad
polym
explor
achiev
effici
pulmonari
gene
express
addit
polyethyleneimin
cation
polym
plga
nanoparticl
exhibit
high
posit
charg
densiti
proton
aqueou
solut
regard
promis
polym
candid
nonvir
vector
deliveri
dna
oligonucleotid
dnaload
plga
nanoparticl
hold
polyethyleneimin
surfac
report
nonvir
gene
vector
human
airway
submucos
epitheli
cell
line
studi
report
presenc
dna
endolysosom
compart
period
h
result
establish
potenti
nanoparticl
gene
deliveri
lung
epithelium
dendrim
synthet
polym
utmost
import
pharmaceut
drug
discoveri
develop
polym
moder
low
toxic
comparison
lipidbas
vector
advantag
versatil
chemic
modif
vitro
knockdown
effici
sirna
antisens
oligonucleotid
aon
deliv
via
dendriplex
lung
alveolar
epitheli
cell
report
previous
dendrim
drug
deliveri
system
threedimension
starshap
branch
macromolecular
network
nanocarri
possess
low
polydispers
index
biocompat
good
water
solubl
dendrim
consist
exterior
interior
layer
interior
layer
respons
control
releas
mechan
reduc
drug
toxic
improv
drug
encapsul
effici
exterior
layer
contain
function
group
respons
conjug
target
moieti
drug
due
uniqu
properti
dendrim
becom
use
drug
deliveri
system
studi
poli
amidoamin
pamam
dendrim
nanocarri
dnc
synthes
effect
pegyl
interact
nanoparticl
evalu
vitro
vivo
model
pulmonari
epithelium
transport
dnc
found
increas
apic
basolater
section
across
polar
monolay
surfac
densiti
peg
increas
behavior
attribut
signific
reduct
charg
densiti
upon
pegyl
result
show
pegyl
potenti
modul
pulmonari
epitheli
transport
intern
dnc
serv
effect
platform
target
lung
tissu
treat
respiratori
diseas
hatano
cowork
synthes
seri
carbosilan
dendrim
hemagglutinin
bind
peptid
evalu
activ
influenza
viru
prepar
dendrim
found
exhibit
strong
antivir
activ
human
virus
dendrimer
nanomateri
prepar
chemic
modif
optim
target
deliveri
small
interf
rna
sirna
pulmonari
vasculatur
poli
propylenimin
poli
amido
amin
dendrim
substitut
differ
length
alkyl
chain
use
combinatori
approach
dendrim
observ
potenti
act
effici
target
agent
pulmonari
deliveri
rna
polymer
micel
capabl
encapsul
water
insolubl
dna
protein
drug
therefor
help
target
deliveri
structur
well
function
featur
polymer
micel
similar
natur
transport
system
like
lipoprotein
viru
import
focu
develop
micel
address
major
problem
associ
drug
ie
drug
resist
purpos
chemic
manipul
done
effect
assess
cellular
interact
biodistribut
encapsul
releas
polymer
nanocarri
hydrophob
drug
transport
target
site
concentr
far
inher
water
solubl
trap
core
micel
studi
pluron
mix
micel
pmm
prepar
evalu
potenti
deliveri
poorli
watersolubl
drug
lung
pmm
load
budesonid
bud
assess
deliveri
transport
stabil
pulmonaryrelev
media
vitro
evalu
formul
evalu
pulmonari
biodistribut
efficaci
vivo
via
intratrach
administr
rat
result
show
excel
stabil
pmm
vitro
may
due
smaller
size
pmm
result
pmm
interact
mucin
thu
diffus
effect
artifici
mucu
overal
result
studi
demonstr
pmm
inhal
formul
import
platform
target
deliveri
water
insolubl
drug
respiratori
diseas
anoth
approach
sustain
deliveri
drug
lung
util
chitosanbas
micel
found
safe
effect
deliv
proteinbas
drug
drug
requir
deliv
special
cell
done
help
nanocarri
like
micel
improv
cellspecif
deliveri
effici
modifi
selfassembl
micel
interf
rna
nanoparticl
samirna
synthes
nanoparticl
design
contain
hydrophob
lipid
hydrophil
polym
end
sirna
capabl
form
micel
solut
spontan
administr
studi
demonstr
samirna
nanoparticl
stabl
sirna
silenc
platform
less
toxic
effect
vivo
target
gene
involv
pathogenesi
respiratori
diseas
gaber
et
al
synthes
beclomethason
dipropion
bdp
load
micel
use
poli
ethylen
oxid
blockdistearoyl
phosphatidylethanolamin
mpegdsp
polym
evalu
sustain
releas
studi
observ
entrap
effici
achiev
bdpload
polymer
micel
along
high
encapsul
effici
sustain
releas
behavior
compar
inhal
properti
increas
biocompat
synthes
polymer
micel
use
util
versatil
deliveri
system
treatment
chronic
obstruct
pulmonari
diseas
asthma
techniqu
merg
sensit
provid
nucleic
acid
amplif
specif
provid
dnadna
hybrid
identifi
virus
like
adenovirus
respons
caus
acut
respiratori
diseas
furthermor
microarray
techniqu
target
gyrbpar
gene
use
identifi
bacteri
speci
cultur
isol
employ
diagnosi
acut
upper
respiratori
infect
techniqu
prove
advantag
convent
pcr
method
identifi
numer
pathogen
clinic
sampl
small
doublestrand
synthet
odn
molecul
consist
transcript
factor
bind
site
involv
regul
transcript
enter
cell
combin
nuclear
transcript
factor
inhibit
attach
consensu
sequenc
target
gene
also
decoy
odn
target
transcript
factor
reduc
airway
inflamm
due
allergen
airway
hyperreact
asthma
new
categori
chemic
engin
oligonucleotid
synthet
analogu
mirna
iv
administr
target
led
decreas
mirna
level
lung
liver
heart
kidney
intestin
caus
prolong
silenc
endogen
mirna
disintegrin
neuropeptid
receptor
may
repres
novel
target
aso
delet
aso
reduc
express
protein
like
alphaactin
promot
apoptosi
therefor
target
gene
may
use
potenti
therapeut
asthma
oligonucleotid
therapi
sever
potenti
clinic
applic
therapeut
import
oligonucleotid
well
understood
potenti
use
variou
disord
like
neurodegen
disord
respiratori
disord
diabet
retinopathi
cancer
oligonucleotid
enter
cell
diffus
larg
entiti
variou
deliveri
method
util
effect
deliveri
oligonucleotid
therapi
although
suffici
inform
avail
biodistribut
overal
pharmacokinet
oligonucleotid
substanti
studi
requir
understand
cellular
intracellular
behavior
oligonucleotid
despit
approv
monoclon
antibodi
like
mepolizumab
omalizumab
reslizumab
oligonucleotid
therapi
might
prefer
monoclon
antibodi
invas
due
parenter
administr
altern
oligonucleotid
local
administ
airway
inhal
aerosol
lesser
invas
method
compar
monoclon
antibodi
addit
threaten
hypersensit
reaction
also
major
drawback
monoclon
antibodi
present
gener
antisens
oligonucleotid
clinic
develop
process
assort
oncolog
neurolog
metabol
cardiovascular
condit
antisens
oligonucleotid
condit
nucleas
suscept
system
circul
lead
short
halflif
rapid
renal
excret
passiv
diffus
via
cell
membran
also
limit
neg
charg
antisens
oligonucleotid
detail
studi
requir
overcom
problem
thu
novel
drug
deliveri
approach
like
nanoformul
need
hour
combat
snag
although
clinic
trial
differ
diseas
condit
ongo
variou
oligonucleotid
therapi
limit
number
clinic
studi
chronic
inflammatori
respiratori
diseas
past
year
mani
oligonucleotid
therapi
approv
fda
complex
neurolog
diseas
like
spinal
muscular
atrophi
duchenn
muscular
dystrophi
success
exampl
may
lead
way
therapeut
util
oligonucleotid
therapi
like
antisens
aptam
chronic
inflammatori
respiratori
diseas
moreov
strategi
chemic
modif
sugar
nucleotid
phosphat
backbon
obligatori
stabil
enhanc
reduct
toxic
synergist
approach
combin
two
antisens
oligonucleotid
enhanc
efficaci
respiratori
diseas
lower
dose
report
studi
rodent
model
deliveri
oligonucleotid
therapeut
regimen
chronic
inflammatori
respiratori
diseas
done
util
nanocarri
oligonucleotid
could
incorpor
determin
cellular
interact
tissu
distribut
use
oligonucleotid
furthermor
chemic
modif
oligonucleotid
target
ligand
also
studi
nutshel
sever
drug
deliveri
system
employ
deliveri
oligonucleotid
like
polymerlipidbas
nanoparticl
target
specif
ligandoligonucleotid
conjug
antibodi
conjug
advanc
novel
approach
like
oligonucleotidebas
microarray
techniqu
decoy
oligodeoxynucleotid
antagomir
target
strategi
use
potenti
treatment
strategi
respiratori
diseas
trend
approv
oligonucleotidebas
therapi
fda
also
show
import
oligonucleotid
moreov
problem
associ
drug
deliveri
also
resolv
use
variou
novel
drug
deliveri
method
describ
review
instanc
via
develop
liposom
niosom
nanoparticl
mucoadhes
target
dendrim
etc
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
